Hudson Bay Capital Management LP Sells 460,500 Shares of uniQure (NASDAQ:QURE)

Hudson Bay Capital Management LP decreased its holdings in shares of uniQure (NASDAQ:QURE) by 72.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 175,000 shares of the biotechnology company’s stock after selling 460,500 shares during the period. Hudson Bay Capital Management LP’s holdings in uniQure were worth $3,090,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in QURE. Invesco Ltd. grew its holdings in uniQure by 453.2% during the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company’s stock worth $10,836,000 after buying an additional 502,684 shares in the last quarter. Sanders Morris Harris LLC boosted its holdings in uniQure by 50.0% during the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after acquiring an additional 34,034 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of uniQure in the 3rd quarter worth $7,360,000. Oppenheimer & Co. Inc. purchased a new stake in shares of uniQure in the fourth quarter valued at about $320,000. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of uniQure in the fourth quarter valued at about $437,000. 78.83% of the stock is owned by institutional investors.

uniQure Stock Performance

NASDAQ:QURE opened at $13.15 on Tuesday. The company has a market capitalization of $720.30 million, a P/E ratio of -2.65 and a beta of 0.10. The business has a fifty day simple moving average of $12.24 and a two-hundred day simple moving average of $12.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The company had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. On average, analysts expect that uniQure will post -3.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on QURE. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of uniQure in a report on Monday, April 21st. Wells Fargo & Company dropped their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 target price on shares of uniQure in a report on Monday. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of uniQure in a research report on Monday. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $37.82.

Insiders Place Their Bets

In other news, CFO Christian Klemt sold 2,916 shares of uniQure stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares in the company, valued at approximately $1,756,501.76. The trade was a 1.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 28,341 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the sale, the chief executive officer now owns 651,454 shares in the company, valued at approximately $6,703,461.66. The trade was a 4.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,830 shares of company stock worth $961,401 over the last quarter. 4.74% of the stock is currently owned by company insiders.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.